Published in Medical Letter on the CDC and FDA, July 2nd, 2000
Tenecteplase, made by Genentech Inc., won FDA approval on June 2, 2000, and will be made widely available as soon as possible to treat the nation's biggest killer, company officials said.
Genentech also makes TPA under the brand name Activase, currently the standard medicine for treating heart clots. Both of the drugs dissolve blockages in a similar fashion, preventing further permanent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA